After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...

Although the market selloff in April has led to softer expectations for IPOs in 2025, many of the positive underlying factors ...

cDivision of Endocrinology, Metabolism & Lipid Research, Washington University School of Medicine, St Louis, MO, USA dDivision of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD ...

Friday’s trading session is showcasing significant movements across the board, with mega-cap stocks like UnitedHealth Group (UNH) and Eli Lilly and Co (LLY) making notable strides, while some ...

"The first quarter of 2025 was a period of focused execution and acceleration at Metsera," said Whit Bernard, Chief Executive Officer of Metsera. "We remain on track to deliver on all of our ...

Metsera, Inc., a clinical-stage biopharmaceutical company focused on treating obesity and metabolic diseases, announced its first quarter 2025 financial results, highlighting significant progress ...